Anti-LC3B antibody [EPR18709] - Autophagosome Marker (Ab192890)

特异性

FURTHER INFORMATION ON SPECIFICITY (Chinese Version) available under the product protocols section. This file includes key technical notes of experience when using this product.

Anti-LC3B antibody [EPR18709] - Autophagosome Marker (ab192890) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IHC-P and WB. Anti-LC3B antibody [EPR18709] - Autophagosome Marker (ab192890) was first used in a scientific publication in 2017 and has been cited over 468 times in peer reviewed journals. It's performance in Western Blot in human, mouse and rat samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-LC3B antibody [EPR18709] - Autophagosome Marker (ab192890) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-LC3B antibody [EPR18709] - Autophagosome Marker (ab192890) has been confirmed by Western Blot testing in LC3B knockout HepG2 cells ( ab277828 ). Anti-LC3B antibody [EPR18709] - Autophagosome Marker (ab192890) has 17 independent reviews from customers. Anti-LC3B antibody [EPR18709] - Autophagosome Marker (ab192890) specifically detects LC3B (UniProt ID: Q9GZQ8; Molecular weight: 15kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone EPR18709 - ab221794. Antibody clone EPR18709 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, Alexa Fluor ® 555 ( ab225382, ab225383, ab307768 ). LC3B is a protein involved in autophagy, a process that helps maintain cellular homeostasis by degrading damaged components. In oncology, LC3B is used as a marker to assess autophagy levels in cancer cells, which can influence tumor progression and response to therapy. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.